Plain-English translation of NCT05793554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a special imaging technology called near-infrared fluorescence imaging with ICG (indocyanine green dye) combined with artificial intelligence can help surgeons accurately identify whether a rectal polyp or tumor is benign or cancerous during surgery. Right now, doctors sometimes can't tell the difference before or even during an operation, which can lead to the wrong treatment choice. This study hopes the new imaging method will give surgeons better real-time information to make the safest decisions for each patient.
Large rectal polyps and early rectal cancers are difficult to diagnose accurately, and getting it wrong can mean a patient receives inadequate treatment or even unnecessary major surgery. Current biopsy methods miss cancer in about 1 in 5 cases, so doctors need a better way to tell benign from cancerous lesions during the operation itself.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would undergo your scheduled rectal surgery as planned. During the operation while you are under anesthesia, the surgeon will inject a small amount of special dye (ICG) into or near the tumor area. A near-infrared camera will then record the fluorescence pattern, which helps identify whether the tissue is benign or cancerous. The surgical video will be securely uploaded for computer analysis. Your care will otherwise proceed according to your surgeon's standard recommendations.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Ireland